BioCentury
ARTICLE | Financial News

Aptinyx proposes $80M IPO

May 23, 2018 11:14 PM UTC

Neurology company Aptinyx Inc. (Evanston, Ill.) proposed to raise $80 million in an IPO on NASDAQ underwritten by J.P. Morgan, Cowen, Leerink and BMO Capital Markets.

The company expects data in 1H19 from a pair of Phase II studies of NYX-2925 to treat pain associated with diabetic peripheral neuropathy and fibromyalgia, respectively. NYX-2925 is a small molecule that acts as an NMDA receptor functional glycine-site partial agonist...

BCIQ Company Profiles

Allergan plc

Aptinyx Inc.

BCIQ Target Profiles

NMDA receptor